AU2017367245B2 - Application of epigenetic chromsomal interactions in cancer diagnostics - Google Patents
Application of epigenetic chromsomal interactions in cancer diagnostics Download PDFInfo
- Publication number
- AU2017367245B2 AU2017367245B2 AU2017367245A AU2017367245A AU2017367245B2 AU 2017367245 B2 AU2017367245 B2 AU 2017367245B2 AU 2017367245 A AU2017367245 A AU 2017367245A AU 2017367245 A AU2017367245 A AU 2017367245A AU 2017367245 B2 AU2017367245 B2 AU 2017367245B2
- Authority
- AU
- Australia
- Prior art keywords
- sequence
- chromosome
- probe
- interaction
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/301—Endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/501—Ligase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/101—Crosslinking agents, e.g. psoralen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428893P | 2016-12-01 | 2016-12-01 | |
| US62/428,893 | 2016-12-01 | ||
| PCT/GB2017/053615 WO2018100381A1 (en) | 2016-12-01 | 2017-11-30 | Application of epigenetic chromsomal interactions in cancer diagnostics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017367245A1 AU2017367245A1 (en) | 2019-06-06 |
| AU2017367245B2 true AU2017367245B2 (en) | 2020-09-24 |
Family
ID=60702831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017367245A Active AU2017367245B2 (en) | 2016-12-01 | 2017-11-30 | Application of epigenetic chromsomal interactions in cancer diagnostics |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11560597B2 (enExample) |
| EP (2) | EP3548633B1 (enExample) |
| JP (2) | JP2019535295A (enExample) |
| KR (1) | KR102481242B1 (enExample) |
| CN (1) | CN110234769B (enExample) |
| AU (1) | AU2017367245B2 (enExample) |
| CA (1) | CA3045070A1 (enExample) |
| ES (1) | ES2971286T3 (enExample) |
| MY (1) | MY190153A (enExample) |
| PL (1) | PL3548633T3 (enExample) |
| TW (1) | TWI865427B (enExample) |
| WO (1) | WO2018100381A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY203765A (en) * | 2019-05-08 | 2024-07-17 | Oxford BioDynamics PLC | Chromosome conformation markers of prostate cancer and lymphoma |
| CN118506860B (zh) * | 2024-07-18 | 2024-10-08 | 广州女娲生命科技有限公司 | 药物表观遗传安全性评价的检测分析方法及系统 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5416405B2 (ja) | 2005-07-04 | 2014-02-12 | エラスムス ユニバーシティ メディカル センター | 染色体コンフォメーションキャプチャ−オン−チップ（４ｃ）アッセイ |
| GB0603251D0 (en) | 2006-02-17 | 2006-03-29 | Isis Innovation | DNA conformation |
| EP2121977B1 (en) * | 2007-01-11 | 2017-06-21 | Erasmus University Medical Center | Circular chromosome conformation capture (4c) |
| US20090117076A1 (en) * | 2007-11-01 | 2009-05-07 | Chen Lei L | Methods For Treating Tumor Cells |
| GB0810051D0 (en) * | 2008-06-02 | 2008-07-09 | Oxford Biodynamics Ltd | Method of diagnosis |
| WO2010036323A1 (en) | 2008-09-25 | 2010-04-01 | University Of Massachusetts Medical School | Method of identifing interactions between genomic loci |
| EP2366162A1 (en) * | 2008-11-18 | 2011-09-21 | Collabrx, Inc. | Individualized cancer treatment |
| RU2603082C2 (ru) | 2010-07-09 | 2016-11-20 | Сергентис Б.В. | Способы секвенирования трехмерной структуры исследуемой области генома |
| CN103547598A (zh) * | 2011-02-24 | 2014-01-29 | 梅里麦克制药股份有限公司 | 包含抗-erbb3药剂的联合治疗 |
| WO2012159025A2 (en) * | 2011-05-18 | 2012-11-22 | Life Technologies Corporation | Chromosome conformation analysis |
| KR20150034209A (ko) * | 2012-06-26 | 2015-04-02 | 델 마 파마슈티컬스 인코포레이티드 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
| CN102827935B (zh) * | 2012-08-29 | 2013-12-18 | 北京大学人民医院 | 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒 |
| GB201320351D0 (en) * | 2013-11-18 | 2014-01-01 | Erasmus Universiteit Medisch Ct | Method |
| CN108377651A (zh) | 2015-06-24 | 2018-08-07 | 牛津生物动力有限公司 | 染色体互相作用的检测 |
| WO2017106290A1 (en) * | 2015-12-14 | 2017-06-22 | The General Hospital Corporation | Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof |
| GB201608000D0 (en) | 2016-05-06 | 2016-06-22 | Oxford Biodynamics Ltd | Chromosome detection |
-
2017
- 2017-11-30 EP EP17817030.4A patent/EP3548633B1/en active Active
- 2017-11-30 PL PL17817030.4T patent/PL3548633T3/pl unknown
- 2017-11-30 JP JP2019528462A patent/JP2019535295A/ja active Pending
- 2017-11-30 ES ES17817030T patent/ES2971286T3/es active Active
- 2017-11-30 WO PCT/GB2017/053615 patent/WO2018100381A1/en not_active Ceased
- 2017-11-30 CA CA3045070A patent/CA3045070A1/en active Pending
- 2017-11-30 CN CN201780085308.2A patent/CN110234769B/zh active Active
- 2017-11-30 EP EP23217260.1A patent/EP4357463A3/en active Pending
- 2017-11-30 AU AU2017367245A patent/AU2017367245B2/en active Active
- 2017-11-30 KR KR1020197019088A patent/KR102481242B1/ko active Active
- 2017-11-30 MY MYPI2019002870A patent/MY190153A/en unknown
- 2017-11-30 US US16/465,133 patent/US11560597B2/en active Active
- 2017-12-01 TW TW106142279A patent/TWI865427B/zh active
-
2022
- 2022-10-28 US US18/050,795 patent/US20230082230A1/en active Pending
- 2022-11-16 JP JP2022183117A patent/JP7579003B2/ja active Active
Non-Patent Citations (1)
| Title |
|---|
| Flavahan, W. et al., ‘Insulator dysfunction and oncogene activation in IDH mutant gliomas’, Nature. 2016, vol.529, pages 110-114 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4357463A3 (en) | 2024-07-17 |
| AU2017367245A1 (en) | 2019-06-06 |
| TWI865427B (zh) | 2024-12-11 |
| MY190153A (en) | 2022-03-31 |
| JP2019535295A (ja) | 2019-12-12 |
| EP3548633C0 (en) | 2024-01-24 |
| CN110234769B (zh) | 2024-06-07 |
| KR102481242B1 (ko) | 2022-12-23 |
| US20190338367A1 (en) | 2019-11-07 |
| KR20190086569A (ko) | 2019-07-22 |
| JP7579003B2 (ja) | 2024-11-07 |
| CN110234769A (zh) | 2019-09-13 |
| NZ753716A (en) | 2024-05-31 |
| JP2023027076A (ja) | 2023-03-01 |
| US20230082230A1 (en) | 2023-03-16 |
| US11560597B2 (en) | 2023-01-24 |
| EP3548633B1 (en) | 2024-01-24 |
| PL3548633T3 (pl) | 2024-04-02 |
| CA3045070A1 (en) | 2018-06-07 |
| EP4357463A2 (en) | 2024-04-24 |
| EP3548633A1 (en) | 2019-10-09 |
| TW201842190A (zh) | 2018-12-01 |
| WO2018100381A1 (en) | 2018-06-07 |
| ES2971286T3 (es) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109661477B (zh) | 与乳腺癌相关的染色体相互作用的检测 | |
| JP7631400B2 (ja) | 遺伝子調節 | |
| US20230082230A1 (en) | Application of epigenetic chromosomal interactions in cancer diagnostics | |
| US11535893B2 (en) | Typing method | |
| KR20220007132A (ko) | 전립선암 및 림프종의 염색체 형태 마커 | |
| HK40111334A (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| HK40013967A (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| HK40013967B (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| EP4028547A1 (en) | Diagnostic chromosome marker | |
| CA3023156C (en) | Detection of chromosome interaction relevant to breast cancer | |
| KR20240006020A (ko) | 염색체 상호작용 마커 | |
| CN117795098A (zh) | 染色体相互作用标志物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: OXFORD BIODYNAMICS PLC Free format text: FORMER NAME(S): OXFORD BIODYNAMICS LIMITED |
|
| FGA | Letters patent sealed or granted (standard patent) |